Issued on behalf of VentriPoint Diagnostics Ltd.
VANCOUVER – Baystreet.ca News Commentary – The healthcare AI market reached $21.66 billion in 2025 and analysts now project growth to $110.61 billion by 2030[1] as artificial intelligence tools transition from experimental technology to hospital-ready solutions. For breakthrough medical technologies to become standard of care, they must prove both clinical effectiveness and economic value[2]. Companies clearing these dual hurdles now stand positioned to capture mainstream adoption as healthcare systems face mounting pressure to deliver better outcomes at lower cost, including developments from VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), CeriBell, Inc. (NASDAQ: CBLL), OneMedNet Corporation (NASDAQ: ONMD), Lunai Bioworks (NASDAQ: LNAI), and Absci Corporation (NASDAQ: ABSI).
MarketsandMarkets forecasts the sector will expand at 38.6% annually through 2030[3], driven by chronic disease burden and data explosion. The FDA cleared over 1,250 AI-enabled medical devices by mid-2025, with hospitals now investing in tools that demonstrate measurable return on investment within 14 months[4].
Ventripoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) recently announced a collaboration with Summit Sciences, a specialized consulting firm, to develop advanced economic and return-on-investment models for its VMS+ cardiac imaging system. The engagement focuses on creating customer-centric financial frameworks that demonstrate cost savings, operational efficiencies, and clinical outcomes associated with the AI-driven 3D heart modeling technology. The new models will integrate advanced analytics and real-world data to provide tailored insights for hospitals, clinics, and cardiology practices, demonstrating clear ROI through process improvement, better accuracy in heart assessments, and optimized resource allocation.
"We are excited to partner with Dana and Summit Sciences to elevate our financial modeling capabilities," said Hugh MacNaught, President & CEO of Ventripoint Diagnostics. "Dana's extensive expertise in healthcare transformation, combined with Summit Sciences' proven track record in data-driven consulting, will enable us to deliver even more compelling value propositions to our customers. This initiative underscores our commitment to not only advancing cardiac care through technology but also ensuring that our solutions make strong economic sense for healthcare providers worldwide."
Dana Friesen, CEO of Summit Sciences, brings over 15 years of experience in financial analysis and ROI optimization within the medical device and healthcare sectors. The firm has delivered billions in lifetime partner savings across clinical agencies over the past two decades. Friesen's experience working with indigenous health networks and community-based models of care across Canada, the United States, and Latin America aligns with Ventripoint's expansion strategy into underserved markets.
In December, the company announced a partnership with Nisg_a'a Valley Health Authority that establishes a global model for delivering advanced cardiac imaging to remote and Indigenous communities. The collaboration centers on Ventripoint's VMS+ system, which transforms standard 2D ultrasound images into 3D volumetric models with MRI-level accuracy. The model follows a hub-and-spoke design where local healthcare providers can acquire ultrasound scans and transmit them digitally to specialists at a central hub for rapid interpretation. Future phases are intended to include additional First Nations communities across Canada, Arctic regions, and rural communities worldwide.
The company also recently appointed David Swetlow as Chief Financial Officer in October. Swetlow brings over 15 years of senior management experience from high-growth medical technology companies, including Sernova, Ondine, Protox, HealthPricer, and QLT. Management views the appointment as a key step in executing a refreshed commercial strategy designed to drive market adoption and revenue growth across international markets.
In late October, Ventripoint announced a collaboration with Providence Health Care Ventures to validate VMS+ at St. Paul's Hospital in Vancouver. The study will evaluate whether AI-enhanced echocardiography can reduce demand for cardiac MRI scans at one of Western Canada's leading cardiac programs. The company also issued a corporate update detailing its shift toward a Device-as-a-Service subscription model. Management believes this approach will shorten sales cycles and build recurring revenue.
CONTINUED… Read this and more news for VentriPoint Diagnostics at: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint
In other industry developments and happenings in the market include:
CeriBell (NASDAQ: CBLL) has received FDA 510(k) clearance for its delirium monitoring solution, the first and only FDA-cleared delirium screening and monitoring device that addresses a condition affecting approximately 31% of ICU patients and up to 80% of those mechanically ventilated. The Ceribell System's AI-powered platform continuously analyzes EEG segments and notifies clinicians when patterns associated with delirium are detected, enabling simultaneous monitoring of seizures, electrographic status epilepticus, and delirium at the bedside.
"Delirium has been under recognized and under treated in critically ill patients for far too long, despite its strong association with poor outcomes," said Jane Chao, PhD, CEO of CeriBell. "With this FDA clearance, Ceribell is proud to expand EEG technology into delirium care, bringing the first objective, continuous monitoring solution to clinicians who urgently need better tools to support these vulnerable patients."
The delirium algorithm was validated through rigorous prospective studies involving 225 adults in critical care environments, with delirium linked to 10% higher six-month mortality risk for every day experienced and 60% higher post-ICU dementia risk compared to patients without ICU delirium. CeriBell has submitted a New Technology Add-on Payment application to the Centers for Medicare and Medicaid Services for this new indication.
OneMedNet Corporation (NASDAQ: ONMD) reported strong momentum following the recent Radiological Society of North America Annual Meeting, where healthcare providers and life sciences companies demonstrated significant interest in the company's updated iRWD platform powered by Palantir Foundry. The platform provides access to regulatory-grade, AI-ready Real-World Data from over 2,130 healthcare sites, with AI-enabled cohort discovery capabilities that reduce feasibility assessments from weeks to minutes for research and post-market surveillance efforts.
"RSNA 2025 confirmed what we've been hearing from the market," said Aaron Green, CEO of OneMedNet. "Providers are seeking a reliable, low-effort way to participate in healthcare innovation and research, while health sciences organizations need scalable, regulatory-grade multimodal datasets that are readily discoverable to accelerate product development and time to market for their solutions. Our platform, built on Palantir Foundry, is addressing these needs effectively."
The company continues expanding its provider network and enhancing multimodal data assets spanning rare diseases, oncology, and cardiology. OneMedNet's proprietary AI also anonymizes data for industries beyond healthcare, including finance and retail, while maintaining rigorous regulatory compliance standards.
Lunai Bioworks (NASDAQ: LNAI) has identified three clinically relevant Parkinson's disease subtypes and prioritized drug targets using its proprietary Augusta Platform, integrating large-scale proteomic data from the Parkinson's Progression Markers Initiative with high-resolution clinical phenotyping across more than 650 participants and 4,500 proteomic probes tracked over multiple years. The AI-powered analysis revealed three outcome-linked patient subtypes: fast motor progression with limited non-motor involvement, rapid neurological and cognitive decline alongside motor worsening, and a female-enriched subtype with broad functional impairment.
"As Parkinson's therapy development continues to struggle with high failure rates and slow progression signals, subtype-specific strategies can materially improve outcomes," said David Weinstein, CEO of Lunai Bioworks. "By linking clinical trajectories to biological pathways, we can design smarter trials, identify partnerable targets, and accelerate development timelines in a highly competitive market."
The company is initiating experimental validation of prioritized targets while advancing toward preclinical model development and biomarker qualification, evaluating co-development and partnering opportunities to apply subtype-specific inclusion criteria to existing Parkinson's assets in a market projected to exceed $13 billion by the 2030s driven by rising prevalence and unmet need.
Absci Corporation (NASDAQ: ABSI) unveiled new human ex vivo data demonstrating that ABS-201, an AI-designed antibody targeting prolactin receptors, effectively stimulates hair growth by regenerating the stem cell niche and promoting key growth modulators in translational human scalp models.
The preclinical data showed the treatment prolonged the anagen growth phase, increased hair matrix keratinocyte proliferation, and uniquely protected and expanded the hair follicle progenitor cell pool by inhibiting prolactin-induced apoptosis of K15+ stem cells while increasing their capacity to generate CD34+ progeny.
ABS-201 demonstrated statistically significant superior hair regrowth compared to minoxidil in preclinical mouse models for androgenetic alopecia, a condition affecting approximately 80 million Americans with limited FDA-approved treatment options showing notable side effects.
The company's Phase 1/2a HEADLINE study is advancing with interim data expected in the second half of 2026, while Absci's Integrated Drug Creation platform combines cutting-edge AI models with a synthetic biology data engine to rapidly design innovative therapeutics. ABS-201 is also being investigated as a potential treatment for endometriosis, expanding the therapeutic application of this AI-designed antibody beyond hair loss treatment.
Article Source: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint
CONTACT:
Baystreet.ca
[email protected]
(805) 649-0042
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
--
SOURCES CITED:
1. https://www.demandsage.com/ai-in-healthcare-stats/
2. https://intuitionlabs.ai/articles/ai-medical-devices-regulation-2025
3. https://www.marketsandmarkets.com/Market-Reports/artificial-intelligence-healthcare-market-54679303.html
4. https://bipartisanpolicy.org/issue-brief/fda-oversight-understanding-the-regulation-of-health-ai-tools/
